Neurofilament Light Chain (NfL): A Sensitive Biomarker for Neurodegeneration
Neurofilament proteins are vital structural components of nerve cells, helping to maintain their shape and function. Of these, neurofilament light chain (NfL) has emerged as a clinically important biomarker. When neurons are damaged or undergoing degeneration, NfL is released into the cerebrospinal fluid (CSF) and blood, where it can be measured. Elevated NfL levels are a highly sensitive indicator of neuroaxonal injury, though it is important to note that NfL is not specific to any single disease—it reflects neuronal damage from a variety of causes.
Clinical Utility of NfL
NfL is increasingly used in both research and clinical practice to detect, monitor, and sometimes predict the course of various neurological conditions. Its applications include:
-
Multiple Sclerosis (MS): NfL rises with disease activity, progression, and treatment response. It can detect subclinical inflammation and axonal damage, sometimes even earlier than MRI.
-
Alzheimer’s Disease: Elevated NfL is associated with cognitive decline, amyloid-beta pathology, and overall progression.
-
Parkinson’s Disease: NfL levels correlate with cortical neurodegeneration, worsening motor symptoms, cognitive changes, and disease severity.
-
Amyotrophic Lateral Sclerosis (ALS): NfL is often elevated before clinical symptoms appear, offering diagnostic and prognostic insights and helping distinguish ALS from other conditions.
-
Huntington’s Disease: NfL can rise before symptom onset, aiding early detection in genetically at-risk individuals.
-
Frontotemporal Dementia (FTD), Dementia with Lewy Bodies (DLB), and Peripheral Neuropathies: NfL reflects disease severity and tracks cognitive and functional decline.
-
Spinocerebellar Ataxias (SCAs): NfL helps stratify pre-symptomatic individuals and monitor early neurodegenerative changes.
-
Traumatic Brain Injury (TBI) and Stroke: Both acute and chronic brain injuries lead to elevated NfL, which correlates with the extent of neuronal damage and recovery outcomes.
-
Hereditary Transthyretin-Mediated (hATTR) Amyloidosis: NfL reflects the severity of nerve damage (polyneuropathy) and helps monitor response to therapy.
-
Concussion and Sports Medicine: NfL is being explored as an objective tool to guide safe return-to-play decisions after mild traumatic brain injury.
Note: Because NfL reflects general neuroaxonal injury, elevated levels should always be interpreted in the context of the patient’s clinical history and other diagnostic findings.
Age-Adjusted Reference Ranges
NfL levels naturally increase with age, even in healthy individuals. For accurate interpretation, age-specific reference intervals (serum/plasma, pg/mL) are used, such as those provided by Labcorp:
| Age (years) | Reference Range (pg/mL) |
|---|---|
| 0–4 | < 1.97 |
| 5–9 | < 1.64 |
| 10–14 | < 1.43 |
| 15–19 | < 1.60 |
| 20–29 | < 1.65 |
| 30–39 | < 1.88 |
| 40–49 | < 2.14 |
| 50–59 | < 3.79 |
| 60–69 | < 4.62 |
| 70–79 | < 7.65 |
| 80+ | < 11.56 |
Summary
Neurofilament light chain is a sensitive and versatile biomarker for detecting and monitoring neurodegenerative and neurological diseases. Its elevation signals ongoing neuroaxonal injury and can provide diagnostic, prognostic, and therapeutic guidance across a wide spectrum of conditions—from MS and Alzheimer’s to concussion and peripheral neuropathies. As research advances, NfL is becoming an integral, non-invasive tool in neurological care, offering objective insights into neuronal health and disease progression.
Neurofilament Light Chain (NfL)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.